[PRNewswire] EpiVax Identifies T cell Epitopes critical to robust T cell
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Asked about the implications of this research, Dr. Lenny Moise, Director of Vaccine Research at EpiVax said: "COVID-19 vaccination studies show neutralizing antibodies are not absolutely required for protection. T cells may play a role in early protection. We have found triggers of T cell immunity that will facilitate development of safe and effective T cell-targeted vaccines."
본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
immune response in SARS-CoV-2, Results Published in NPJ Vaccines
(PROVIDENCE, R.I., May 17, 2021 PRNewswire=연합뉴스) EpiVax, Inc. ("EpiVax") announces the publication "Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation [https://www.nature.com/articles/s41541-021-00331-6.epdf?sharing_token=r6TuVy2iZ2OLaZ8WPVhyVdRgN0jAjWel9jnR3ZoTv0MPUDK4mOfq0xHPmqcwzQttlsiGIIWmvRmSlV_BgZW3UjTa6cyiBfmDjxt9s7FxV7KN8AWiOWezhs7jd6MAxBbCt_SpEHsJNXNQ6UB5PJ8OUTlfk35OsUKoDdv1K0tELBc= ]" in NPJ Vaccines. This research identifies peptide epitopes associated with T cell immunity to SARS-CoV-2 and confirms that recovering patients produce a memory immune response to iVAX-predicted epitopes. T cell immunity is an important component to long-term immune protection and is critical for vaccine developers to create future vaccines that activate a robust T cell immune response.
T cell immune responses to COVID-19 vaccines are not yet well characterized, as initial vaccine development focused on antibody responses. As global focus shifts to providing long-term immunity, researchers are keen to address T cell immunity with follow-on vaccinations/booster shots. EpiVax researchers confirmed the existence of 18 T cell epitopes previously described in peer-reviewed research, but notably also identified 14 additional epitopes that are described here for the first time. These epitopes were also found to be highly conserved across the sequences of all identified SARS-CoV-2 variants, indicating a T cell-directed vaccine would be more resilient than existing vaccines to new variants.
Long considered preeminent experts on T cell immunity and T cell driven vaccine design, EpiVax researchers and collaborators have been developing a SARS-CoV-2 vaccine, EPV-CoV19 [https://epivax.com/pipeline/epv-cov19 ]. In a preclinical immunization study in HLA- transgenic mice, EPV-CoV-19 stimulated a strong type 1-skewed T cell response, that is characteristic of safe COVID-19 vaccines.
Asked about the implications of this research, Dr. Lenny Moise, Director of Vaccine Research at EpiVax said: "COVID-19 vaccination studies show neutralizing antibodies are not absolutely required for protection. T cells may play a role in early protection. We have found triggers of T cell immunity that will facilitate development of safe and effective T cell-targeted vaccines."
For a free online version of this published research visit NPJ Vaccines here [https://www.nature.com/articles/s41541-021-00331-6.epdf?sharing_token=r6TuVy2iZ2OLaZ8WPVhyVdRgN0jAjWel9jnR3ZoTv0MPUDK4mOfq0xHPmqcwzQttlsiGIIWmvRmSlV_BgZW3UjTa6cyiBfmDjxt9s7FxV7KN8AWiOWezhs7jd6MAxBbCt_SpEHsJNXNQ6UB5PJ8OUTlfk35OsUKoDdv1K0tELBc= ].
About EpiVax:
EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies.
For more information about EpiVax, visit www.epivax.com.
For more information on EpiVax's SARS-CoV-2 vaccine candidate (EPV-CoV19) please contact us here [https://epivax.com/pipeline/epv-cov19 ].
Press Contact:
Katie Porter, Business Development Manager
EpiVax
kporter@epivax.com
Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg
EpiVax is an immunology company founded in 1998. We develop and employ extensive analytical capabilities in the field of computational immunology. We assess protein therapeutics for immunogenic risk and design more effective (and safer) vaccines. www.EpiVax.com.
Source: EpiVax Inc.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 수도권과 강원도 중심 비…남부·중부지방 폭염 특보 | 연합뉴스
- 與전대 '김여사 문자' 파문…韓 반발·非韓 '총선책임론' 재점화(종합) | 연합뉴스
- 경찰 수사심의위, '채상병 사건' 임성근 전 사단장 불송치 의견 | 연합뉴스
- 시청역 역주행 사고 차량 보험이력 보니…지난 6년간 6번 사고 | 연합뉴스
- 바이든 "대선 후보 사퇴 완전 배제…트럼프와 다시 토론할 것"(종합) | 연합뉴스
- 美 S&P 500·나스닥 또 사상 최고치 마감…9월 금리인하 기대↑(종합) | 연합뉴스
- 민수용 도시가스요금 6.8% 인상…4인 가구 기준 월 3천770원↑(종합) | 연합뉴스
- 7월 국회 파행 불가피…방송법·채상병특검 재표결 '뇌관'(종합) | 연합뉴스
- "이란 대선 결선, 개혁 성향 페제시키안 초반 앞서" | 연합뉴스
- 英스타머 내각 발표…'흙수저' 장관들, 첫 여성 재무장관 | 연합뉴스